Efficacy of gemcitabine for locally advanced pancreatic cancer: Comparison with 5-fluorouracil-based chemoradiotherapy

Chemotherapy

Volumn 54, Issue 4, 2008, Pages 302-308

  Tada, Minoru ^a,b   Arizumi, Masatoshi ^a   Nakai, Yousuke ^a   Sasaki, Takashi ^a   Kogure, Hirofumi ^a   Togawa, Osamu ^a   Matsubara, Saburo ^a   Tsujino, Takeshi ^a   Hirano, Kenji ^a   Sasahira, Naoki ^a   Isayama, Hiroyuki ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE   (Japan)

Author keywords

Chemotherapy; Ductal pancreatic carcinoma; Gemcitabine

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE; RAMOSETRON;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA AND VOMITING; PANCREAS CANCER; PANCYTOPENIA; PRIORITY JOURNAL; RADIOCHEMOTHERAPY; RASH; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 48749090509     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151226     Document Type: Article

References (39)

1. Tada M, Kawabe T, Arizumi M, Togawa O, Matsubara S, Yamamoto N, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tateishi K, Isayama H, Toda N, Yoshida H, Omata M: Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol 2006;4:1265-1270.
2. Warshaw AL, Castillo CF: Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
3. Rosewicz S, Wiedenmann B: Pancreatic carcinoma. Lancet 1997;349:485-489.
4. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Klöppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data from the Finnish cancer registry. Gut 2005;54:385-387.
5. Lockhart AC, Rothenberg ML, Berlin JD: Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-1654.
6. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;ii:865-867.
7. Gastrointestinal Tumor Study Group: Therapy of locally unresected pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-1710.
8. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755.
9. Okusaka T, Okada S, Tokuuye K, Wakasugi H, Saisho H, Ishikawa O, Matsuno S, Sato T, Sato K: Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer 2001;91:1384-1389.
10. Wilkowski R, Thoma M, Weingandt H, Duhmke E, Heinemann V: Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP 2005;6:216-230.
11. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy PK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
12. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
13. Stornilo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine: results for over 3,000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
14. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y: Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
15. Neoptolemos JP, Cunningham D, Frisee H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine F, Hickey H, Raraty MGT, Ghaneh P, Buchler MW: Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003;14:675-692.
16. Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M, Oshima K, Isayama H, Ogawa S, Motokura T, Chiba S, Ohtomo K, Omata M, Hirai H: Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005;79:821-827.
17. National Cancer Institute Common Toxicity Criteria (Version 2). Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, 1999.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. 2. Analysis and examples. Br J Cancer 1977;35:1-39.
21. Oken MM, Creech RH, Tormey D, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
22. McGinn CJ, Zalupsli MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemictabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-4208.
23. Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL: Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;54:670-676.
24. de Lange SM, van Groeningen CJ, Meijer OWM, Cuesta MA, Langendijk JA, van Riel JMGH, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G: Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212-1217.
25. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-677.
26. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
27. Takahashi Y, Mai M, Sawabu N, Nishioka K: A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreatic cancer. Pancreas 2005;30:206-210.
28. Sumii T, Fujimori N, Nakamura T, Senjyu T, Horikawa Y, Funakoshi A: Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer (in Japanese). Jpn J Cancer Chemother 2006;33:1261-1265.
29. Takahashi Y, Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 1995;87:1262-1263.
30. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson N, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N: Scandinavian Breast Group 6401 study. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Lancet 2000;356:1384-1391.
31. Moore MJ: A new combination in the treatment of advanced pancreatic cancer. Semin Oncol 2005;32:5-6.
32. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002;20:3270-3275.
33. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3783.
34. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.
35. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-3516.
36. Tanno S, Nakano Y, Osanai M, Koizumi K, Izawa T, Habiro A, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Kohgo Y: A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer. Chemotherapy 2006;52:98-102.
37. Alldinger I, Tsamaloukas AG, Germing U, Hosch SB, Knoefel WT: Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy. Chemotherapy 2007;53:356-359.
38. Kim H, Park J-H, Shin SJ, Kim M-J, Bang S-J, Park NH, Nah YW, Nam CW, Joo KR, Min YJ: Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin: a phase II study. Chemotherapy 2008;54:54-62.
39. Ishikawa T: Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer? World J Gastroenterol 2007;13:4306-4309.